Kynexis is advancing a potential first-in-class approach to restore cognitive function for people living with brain diseases
Kynexis is advancing a potential first-in-class approach to restore cognitive function for people living with brain diseases. The company is developing KYN-5356, a first-in-class KAT-II inhibitor designed to lower elevated kynurenic acid (KYNA), a key biological driver of cognitive impairment in disorders including schizophrenia and Alzheimer's disease.